PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
Elm EV supply and install electrical vehicle charging equipment to the UK market. Elm EV have started to develop a new range of charging products and are looking to expand their reach to international markets.
days to go:
Expired
investment:
£12,420
Glint is a proprietary multi-currency platform that allows users to buy, save, spend and send real gold and other currencies, digitally with its application. The company asserts that its scalable technology enables its clients to use their currencies such as GBP, USD, EUR and Gold, with Glint's UK, EU and US-issued Mastercards in 210 countries worldwide. Glint also points out that its Peer-to-Peer (P2P) Service, Glint It!, allows clients to send and receive gold and currency between Glint accounts in over 160 countries. The company has raised £20 million in equity funding to date, reached 79,000 registered clients, and overseen over £158 million worth of transactions on its platform. Glint will use the investment to maximise revenue, organically grow its business, increase its registered customer base to 250,000 in 2021, and hire key personnel across various portfolios.
days to go:
Expired
investment:
£3,072,539
Docandu is an innovative digital health platform designed both for patients & doctors, making digital healthcare accessible from anywhere. Docandu aims to be a key tech health service provider, starting from Greece, improving the existing national and private health care services. The global digital health market is estimated to be worth $536 Billion by 2025. To date, they have developed two separate apps for doctors and patients. They have also received an angel investment of 100,000 Euros and sponsorship of $25,000 from Microsoft. The company has initiated early-stage relationships with a couple of Greek public and private health entities. With the proceeds, they will execute their go-to-market strategy and make global health ID a reality, by expanding its affiliate network of doctors, health providers and public health systems.
days to go:
Expired
investment:
£70,900
Thyngs is a touch-free instant payment platform for businesses and charities. It has around 20 active re-seller partners for new sectors and markets. The company is working with PricewaterhouseCoopers (PwC) as part of its raise programme and actively engaging with several Series A Venture Capitalist (VC) funds intending to raise £4-5 million in late 2021 to scale its business. Thyngs aggregates various payment partners including PayPal, Worldpay, Apple Pay and Google Pay. The company was the cashless donation platform for 210,000 fundraising events for Macmillan's 'World's Biggest Coffee Morning', which raised £27 million in 2019. Many reputed organisations such as Warner Bros, Royal British Legion, Wasabi, National Geographic, and ANZ Bank are working with Thyngs. The company will use the investment to enhance its marketing campaign, bolster its sales team, work on data security and integrations on its platform, and expand the account management team to boost its business.
days to go:
Expired
investment:
£329,591
nHouse is a disruptive housing company that builds beautiful eco-friendly homes offsite in the UK. It makes houses by using modular methods wherein individual parts of a house are constructed separately in a factory before being transported and assembled together at the building site. The company's houses have Buildoffsite Property Assurance Scheme (BOPAS) accreditation; they are mortgage friendly and have a 60-year structural warranty. They have a demand of 300,000 houses every year in the UK. Major UK newspapers like the FT, The Times, The Guardian, and The Sun have covered nHouse's work. In 2025, the company is aiming to generate a return for shareholders via either a listing or trade sale. The investment will support working capital to extend the runway of nHouse into 2021.
days to go:
Expired
investment:
£147,480
DeadHappy is a digital-first life insurance provider that aims to disrupt the £3.7 billion life insurance market. The company claims that traditional life insurance is complex, expensive, and inflexible. DeadHappy argues that it can offer customers a cheap, flexible and enjoyable alternative. It has developed a unique pay-as-you-go life insurance product with a rolling 10 year guarantee of cover. A simple sign-up process allows customers to answer only 4 medical questions & obtain cover in under 5 minutes, on-line, via their mobile phone. The company's proprietary Deathwish Platform enables customers to personalise their life insurance by creating ‘Deathwishes’. In 2020, DeadHappy reached 120,000+ total deathwishes and has sold 7,800+ total life insurance policies. The company will use 35% of the investment for company growth, 30% for technology development, 20% for product development, and 15% to build partnerships.
days to go:
Expired
investment:
£2,703,820
